Moderna Stock Soars 13.93%, Hits Intraday High of $29.20

Moderna, Inc. has experienced significant activity today, with the stock rising by 13.93% and reaching an intraday high of USD 29.20. This performance stands in contrast to the S&P 500, which remained flat at 0.0% for the day. Over the past week, Moderna has shown a 7.2% increase, while its one-month performance reflects an 8.94% gain. However, the stock's longer-term trajectory reveals challenges, with a notable decline of 48.57% over the past year and a staggering 81.36% drop over the last three years.
Despite today's gains, Moderna's financial metrics indicate underlying difficulties. The company reported net sales of USD 142 million, a significant decrease of 82.12%, and a net profit loss of USD 2,916 million for the first nine months, reflecting a 30.35% decline. Additionally, raw material costs have surged by 172.78% year-over-year. With a market capitalization of USD 9,661 million, Moderna operates within the small-cap segment of the pharmaceuticals and biotechnology industry, facing consistent underperformance against the S&P 500 benchmark.